Larkspur Health Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on business in the biotechnology sector in the United States. The company was incorporated in 2021 and is based in Bridgewater, New Jersey.
IPO Year: 2022
Exchange: NASDAQ
Website: https://lsprhealth.com
| Date | Price Target | Rating | Analyst |
|---|
S-8 - ZyVersa Therapeutics, Inc. (0001859007) (Filer)
8-K - ZyVersa Therapeutics, Inc. (0001859007) (Filer)
8-K - ZyVersa Therapeutics, Inc. (0001859007) (Filer)
424B4 - ZyVersa Therapeutics, Inc. (0001859007) (Filer)
EFFECT - ZyVersa Therapeutics, Inc. (0001859007) (Filer)
S-1/A - ZyVersa Therapeutics, Inc. (0001859007) (Filer)
8-K - ZyVersa Therapeutics, Inc. (0001859007) (Filer)
S-1/A - ZyVersa Therapeutics, Inc. (0001859007) (Filer)
424B3 - ZyVersa Therapeutics, Inc. (0001859007) (Filer)
8-K - ZyVersa Therapeutics, Inc. (0001859007) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)
4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)
3 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)
3 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)
3 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)
3 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)
4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)
4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)
4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)
4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)
Fastest customizable press release news feed in the world
ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product candidates for treatment of renal and inflammatory diseases WESTON, Fla. and BRIDGEWATER, N.J., Dec. 12, 2022 /PRNewswire/ -- ZyVersa Therapeutics, Inc. ("ZyVersa"), a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop products for patients with renal or inflammatory diseases with high unmet medical needs, and Larkspur Health Acquisition Corp. (NASDAQ:LSPR, Larkspur", ))), a blank-check special purpose acquisition company, are pleased to announce closing of their previously announced business combination.
Annual Inflammasome Summit unites world renowned experts in inflammasome-targeted drug development and academia to share information and address knowledge gaps in this rapidly evolving fieldZyVersa is well positioned in the emerging inflammasome space with a highly differentiated inflammasome ASC inhibitor (IC 100), which has potential to treat a broad range of inflammatory diseasesBy inhibiting ASC, IC 100 inhibits multiple types of inflammasomes, not just NLRP3, to stop initiation of the inflammatory cascade and progression of damaging inflammation that is pathogenic in inflammatory diseasesZyVersa and Larkspur Health entered into a definitive business combination agreement on July 20, 202
Special meeting of Larkspur stockholders scheduled for December 8, 2022, to vote on the proposed business combination of Larkspur with ZyVersaZyVersa is a clinical stage biopharmaceutical company with two licensed proprietary product platforms, a cholesterol efflux mediator targeting multiple renal diseases, and an inflammatory ASC inhibitor targeting numerous inflammatory diseasesZyVersa and Larkspur Health entered into a definitive business combination agreement dated July 20, 2022, as amended (the "Business Combination Agreement") Combined company expected to be named ZyVersa Therapeutics, Inc. and listed on NASDAQ in fourth quarter of 2022 under ticker "ZVSA"BRIDGEWATER, N.J. and WESTON,
Mr. Glover will be joining four other life science executives in a General Session titled, CEO Panel: Learn from the expertsZyVersa is a clinical stage biopharmaceutical company with two licensed proprietary product platforms targeting renal and inflammatory diseasesZyVersa and Larkspur Health entered into a definitive business combination agreement on July 20, 2022, which is expected to be completed in fourth quarter of 2022Combined company expected to be named ZyVersa Therapeutics, Inc. and listed on NASDAQ under ticker "ZVSA"WESTON, Fla. and BRIDGEWATER, N.J., Oct. 28, 2022 /PRNewswire/ -- ZyVersa Therapeutics, Inc. ("ZyVersa"), a clinical stage specialty biopharmaceutical company leverag
Aggregate committed financing in support of the business combination now at $10.0 millionZyVersa and Larkspur entered into a definitive business combination agreement on July 20, 2022ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product candidates to address significant unmet medical needs in patients with renal and inflammatory diseases Transaction expected to be completed in fourth quarter of 2022Combined company expected to be named ZyVersa Therapeutics, Inc. and listed on NASDAQ under ticker "ZVSA"BRIDGEWATER, N.J. and WESTON, Fla., Sept. 27, 2022 /PRNewswire/ -- ZyVersa Therapeutics, Inc. ("ZyVersa"), a clinical stage specialty biopharmaceutical company
Age-related chronic inflammation induced by activation of NLRP1 inflammasomes is implicated in development and progression of neurodegenerative diseases such as Alzheimer's and Parkinson's diseases IC 100 research was conducted at the University of Miami Miller School of Medicine by acclaimed experts in immunology, and leaders at the forefront of inflammasome research IC 100, a novel monoclonal antibody inflammasome ASC inhibitor, targets multiple types of inflammasomes, including NLRP1, to block initiation and perpetuation of damaging chronic inflammation WESTON, Fla. and BRIDGEWATER, N.J., Aug. 22, 2022 /PRNewswire/ -- ZyVersa Therapeutics, Inc. ("ZyVersa"), a clinical stage specialty bi
BRIDGEWATER, N.J. and WESTON, Fla., Aug. 15, 2022 /PRNewswire/ -- Larkspur Health Acquisition Corp. (NASDAQ:LSPR, Larkspur", ))), a blank-check special purpose acquisition company, and ZyVersa Therapeutics, Inc. ("ZyVersa"), a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop product candidates that address unmet medical needs in the areas of renal and inflammatory diseases, are pleased to announce that Larkspur has filed with the U.S. Securities and Exchange Commission (the "SEC") a registration statement on Form S-4 (the "Registration Statement") in connection with the business combination agreement (the "Transaction") between Larks
ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product candidates to address significant unmet medical needs of patients with renal and inflammatory diseases Lead renal product candidate, phase 2a-ready VAR 200, mediates removal of excess intracellular lipids that contribute to kidney damage leading to end-stage renal diseaseLead anti-inflammatory product candidate, inflammasome ASC inhibitor (IC 100), blocks initiation and perpetuation of damaging inflammation that's pathogenic in a multitude of inflammatory diseasesTransaction proceeds will advance clinical evaluation of VAR 200 and progress IC 100 into the clinicCombined company to have an implied initial
This live feed shows all institutional transactions in real time.
SC 13G/A - ZyVersa Therapeutics, Inc. (0001859007) (Subject)
SC 13G - ZyVersa Therapeutics, Inc. (0001859007) (Subject)
SC 13G/A - ZyVersa Therapeutics, Inc. (0001859007) (Subject)
SC 13G/A - ZyVersa Therapeutics, Inc. (0001859007) (Subject)
SC 13G - ZyVersa Therapeutics, Inc. (0001859007) (Subject)
SC 13D/A - ZyVersa Therapeutics, Inc. (0001859007) (Subject)
SC 13D/A - ZyVersa Therapeutics, Inc. (0001859007) (Subject)
SC 13G - ZyVersa Therapeutics, Inc. (0001859007) (Subject)
SC 13G/A - ZyVersa Therapeutics, Inc. (0001859007) (Subject)
SC 13G - ZyVersa Therapeutics, Inc. (0001859007) (Subject)